Avenzo Therapeutics to Present New Phase 1 Data on AVZO-021 (CDK2 Inhibitor) at the 2026 American Society of Clinical Oncology Annual Meeting
Avenzo Therapeutics has announced a significant milestone in its ongoing efforts to develop innovative cancer therapies, revealing that new clinical data for its investigational drug AVZO-021 will be show cased at the 2026 American Society of Clinical Oncology Annual Meeting. This highly anticipated global oncology conference is scheduled to take place in Chicago from May 29 to June 2, 2026, and will bring together leading oncologists, researchers, and healthcare professionals from around the world.
The company, which focuses on advancing next-generation oncology treatments, confirmed that an abstract highlighting updated findings from its ongoing Phase 1/2 clinical trial has been accepted for poster presentation. This study centers on AVZO-021, a selective cyclin-dependent kinase 2 (CDK2) inhibitor that is being evaluated both as a standalone therapy and in combination with other treatments for patients with advanced solid tumors.
AVZO-021 represents a promising development in targeted cancer therapy. Cyclin-dependent kinases, particularly CDK2, play a critical role in regulating the cell cycle. In many cancers, dysregulation of these kinases leads to uncontrolled cell proliferation. By selectively inhibiting CDK2, AVZO-021 aims to interrupt tumor growth while minimizing off-target effects often associated with less selective therapies. The drug is being positioned as a potential “best-in-class” candidate, meaning it could offer superior efficacy or safety compared to other therapies in the same category.
The upcoming presentation at ASCO 2026 will provide updated safety and efficacy results from the Phase 1 portion of the study. Early-phase trials such as this are essential for determining the optimal dosage, evaluating tolerability, and identifying preliminary signs of clinical benefit. According to Avenzo, the data will offer further insight into how patients are responding to AVZO-021 and whether the therapy demonstrates a favorable risk-benefit profile.
The study itself is notable for its broad scope and inclusive design. It is a first-in-human, multi-part Phase 1/2 trial that explores AVZO-021 in a range of advanced solid tumors. These include hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2−) breast cancer, as well as tumors characterized by amplification of the cyclin E1 (CCNE1) gene. Both of these cancer subtypes are areas of high unmet medical need, particularly in cases where patients have progressed on existing therapies.
Hormone receptor–positive, HER2-negative breast cancer is one of the most common forms of breast cancer, and while treatments have improved significantly in recent years, resistance to therapy remains a major clinical challenge. Similarly, CCNE1 amplification is associated with aggressive tumor behavior and poor prognosis across multiple cancer types. By targeting CDK2, which is closely linked to cyclin E1 activity, AVZO-021 may offer a more precise and effective approach for these patient populations.
The poster presentation will be part of the “Breast Cancer—Metastatic” session, reflecting the relevance of the study’s findings to advanced stages of disease. The abstract, identified by number 1094, outlines the design and outcomes of the trial, including both monotherapy and combination treatment strategies. Combination approaches are of particular interest in oncology, as they may enhance therapeutic efficacy by targeting multiple pathways simultaneously or overcoming resistance mechanisms.
Attendees at the conference will be able to view the poster on June 1, 2026, between 1:30 p.m. and 4:30 p.m. Central Time, at Poster Board 208. During this session, researchers and clinicians will have the opportunity to engage directly with the study team, ask questions, and discuss the implications of the findings. Such interactions are a key component of scientific conferences, fostering collaboration and accelerating the translation of research into clinical practice.
The acceptance of this abstract by ASCO underscores the scientific and clinical significance of Avenzo’s research. The ASCO Annual Meeting is widely regarded as one of the most prestigious events in oncology, serving as a platform for groundbreaking discoveries and practice-changing data. Companies and academic institutions alike compete for the opportunity to present their work at this conference, and inclusion is often seen as a mark of quality and relevance.
For Avenzo Therapeutics, this presentation represents an important step forward in the development of AVZO-021. Positive results from early-phase studies can pave the way for later-stage trials, regulatory engagement, and ultimately, potential approval. While it is still early in the clinical development process, the updated data may help validate the therapeutic strategy and support continued investment in the program.
Beyond the specifics of AVZO-021, the announcement also highlights broader trends in oncology drug development. There is a growing emphasis on precision medicine, where treatments are tailored to the molecular characteristics of a patient’s tumor. Targeted therapies like CDK2 inhibitors are designed to exploit specific vulnerabilities in cancer cells, potentially leading to more effective and less toxic treatments.
Additionally, the integration of biomarker-driven approaches—such as selecting patients based on CCNE1 amplification—reflects a shift toward more personalized and data-driven clinical trials. This approach not only improves the likelihood of success but also ensures that patients receive therapies that are most likely to benefit them.
The collaboration and knowledge-sharing facilitated by events like the ASCO Annual Meeting play a crucial role in advancing the field. By presenting updated clinical data, Avenzo contributes to the collective understanding of cancer biology and treatment, helping to inform future research and clinical decision-making.
As the oncology community continues to seek new solutions for patients with advanced and treatment-resistant cancers, innovations like AVZO-021 offer a glimpse of what the next generation of therapies may look like. While further studies will be needed to confirm its efficacy and safety, the progress reported by Avenzo Therapeutics is an encouraging development in the ongoing fight against cancer.
In summary, Avenzo Therapeutics’ upcoming presentation at ASCO 2026 will showcase important new data from its Phase 1/2 study of AVZO-021, a selective CDK2 inhibitor with the potential to address significant unmet needs in oncology. With its focus on targeted therapy, combination strategies, and biomarker-driven patient selection, the study reflects the cutting edge of cancer research and underscores the company’s commitment to advancing innovative treatments for patients worldwide.
About Avenzo Therapeutics
Avenzo Therapeutics is a clinical-stage biotechnology company focused on developing next-generation oncology therapies for patients. The company’s pipeline includes potential best-in-class small molecules and antibody-drug conjugates (ADCs). Avenzo’s small molecule inhibitors, AVZO-021 and AVZO-023, are novel, highly potent and selective inhibitors of CDK2 and CDK4, respectively, which are key enzymes involved in cell cycle regulation. AVZO-021 is being studied in a Phase 1 study for the treatment of advanced solid tumors and in combinations in HR+/HER2- metastatic breast cancer. AVZO-023 is being studied in a Phase 1/2 study in combinations for the treatment of HR+/HER2- metastatic breast cancer. Avenzo’s first ADC drug candidate, AVZO-1418, is a potential best-in-class, EGFR/HER3 bispecific ADC that is being studied in a Phase 1/2 study for the treatment of advanced solid tumors. Avenzo’s second ADC drug candidate, AVZO-103, is a potential best-in-class, Nectin4/TROP2 bispecific ADC that is being studied in a Phase 1/2 study for the treatment of advanced solid tumors
